Redefining and optimising contemporary bladder cancer care

Aims and objectives of this session
Bladder cancer is a frequently occurring disease with a high mortality rate despite optimal treatment. This session will highlight the proper management of non-muscle invasive bladder cancer, including ongoing debate about conservative management in T1 tumour or the rhythm of follow-up in low grade tumour. Additionally, the therapeutic impact of the extent of lymphadenectomy during radical cystectomy will be stated. Potential indications and contraindications, such as comorbidity, are related to treatment choice. The implementation of fast-track programs of rehabilitation to enhance postsurgical recovery after cystectomy and the quality of life after urinary diversion will be discussed.

During the plenary sessions, French and Spanish translation will be provided. Please collect your headset in the session room prior to the start of the session and return it after the session.

Meet the speakers of the plenary session:
Delegates are able to meet the speakers of the plenary session immediately at the end of the session in the foyer of the eURO Auditorium (Level 0). Do not miss this opportunity to meet and greet the speakers and to consult them for any questions you may have.

08:00 - 09:00
Case discussion Perfect management of T1 bladder cancer
Moderator: G.N. Thalmann, Berne (CH)

08:00 - 08:04
Case presentation
G.N. Thalmann, Berne (CH)

08:04 - 08:18
Perfect transurethral resection
M. Babjuk, Prague 5 (CZ)

08:18 - 08:32
Perfect pathology report
R. Montironi, Ancona (IT)

08:32 - 08:46
Adjuvant treatment
J.A. Witjes, Nijmegen (NL)

08:46 - 09:00
Perfect decision re cystectomy
A.M. Kamat, Houston (US)

09:00 - 09:30
Debate Do we need a follow-up in low grade bladder tumour after 12 months?
Moderator: M. Brausi, Modena (IT)

09:00 - 09:15
Yes (EAU Guidelines)
M. Burger, Regensburg (DE)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:15 - 09:30</td>
<td><strong>No (NICE Guidelines)</strong>&lt;br&gt;H. Mostafid, Guildford (GB)</td>
</tr>
<tr>
<td>09:30 - 10:00</td>
<td><strong>State-of-the-art lecture</strong>&lt;br&gt;The evidence for the extent of lymphadenectomy in TCC</td>
</tr>
<tr>
<td>09:30 - 09:45</td>
<td><strong>Presenter</strong>&lt;br&gt;J.E. Gschwend, München (DE)</td>
</tr>
<tr>
<td>09:45 - 10:00</td>
<td><strong>Discussant</strong>&lt;br&gt;S. Lerner, Houston (US)</td>
</tr>
<tr>
<td>10:00 - 10:15</td>
<td><strong>State-of-the-art lecture</strong>&lt;br&gt;Enhanced Recovery After Surgery (ERAS) for bladder cancer: Non-surgical options to improve outcomes of cystectomy&lt;br&gt;J.W.F. Catto, Sheffield (GB)</td>
</tr>
<tr>
<td>10:15 - 10:30</td>
<td><strong>State-of-the-art lecture</strong>&lt;br&gt;What determines QoL after urinary diversion and how to measure it?&lt;br&gt;W. Artibani, Verona (IT)</td>
</tr>
</tbody>
</table>